HIV VACCINES IN CLINICAL-TRIALS - A RECOMBINANT CANARYPOX VIRUS, A CHIMERIC RGP160 AND A SYNTHETIC PEPTIDE IN PRIME/BOOST COMBINATIONS | AMiner